Hypertension is associated with lower risk of dementia-related outcomes in aECAD patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Dementia prevention education increasingly seeks to translate evidence about modifiable risk factors into meaningful public engagement and preventive action. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Among 1,288,359 women, 20,070 with AUD were matched to 100,339 controls. 3 key findings →
Design: prospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
The 2,885 participants had a mean age of 69.5 years. 4 key findings →
Design: longitudinal study Participants: 2,885 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neuroticism, a personality trait characterized by the predisposition to experience intense and frequent negative emotions, has been associated with an increased risk of Alzheimer’s disease (AD). 5 key findings →
Participants: 1,277 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is a progressive condition that impairs cognitive processes such as memory, decision-making, and the ability to manage daily activities. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, pathological tau aggregation, and neuronal loss. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Nerve Growth Factor (NGF) supports neuronal survival, plasticity, and growth by binding to p75NTR and TrkA receptors. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease involves progressive necroptosis of neurons, and the associated cognitive deficits can be mitigated by inhibiting cAMP-degrading phosphodiesterase 4D (PDE4D). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The multifactorial interventions implemented in community settings showed no effect on dementia onset or health outcomes. 5 key findings →
Participants: 256 Evidence: low
Full summary, score breakdown and related studies → Original source
We used the September 2013 age-based rollout of the live-attenuated shingles vaccine in England as a natural experiment to estimate the effect of vaccine eligibility on shingles and dementia diagnoses in linked hospital records. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
16/100
Late-onset unexplained epilepsy is a potential harbinger of dementia, likely driven by network hyperexcitability that facilitates amyloid-β release and tau propagation. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
16/100
Neuroexposome research investigates associations between physical, chemical, biological, and psychosocial factors and neurological health. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 859 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Using real world data to visualize longitudinal modifiable dementia risk factors in the community through an online interactive map
- Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation
- Rural-urban differences in modifiable dementia risk factors among U.S. populations aged 45 years or older
- Mediterranean diet and cognitive function in older adults
- Closing the Gap Between Observational Research and Randomized Controlled Trials for Prevention of Alzheimer Disease and Dementia
- Statins for the prevention of dementia
- Novel Nutraceutical Compounds in Alzheimer Prevention
- Age-related hearing loss and dementia risk across the lifespan: mechanisms, equity, and prevention
- Doctor, Should I Use Computer Games to Prevent Dementia?
- Physical Activity Interventions in Preventing Cognitive Decline and Alzheimer-Type Dementia: A Systematic Review
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →